Immunome IMNM
NASDAQ IMNM
$18.08 +0.16 (+0.89%)
As of: Oct 21, 2026 · 11:36 AM EDT

Immunome (IMNM) Debt Ratio (2020 - 2021)

Updated

Immunome's Debt Ratio came in at 0.01 for Q1 2021, up 4.5% from the prior quarter.

Analysis

Immunome (IMNM) Debt Ratio (2020 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,130.38 Bn 1,098.96 Bn 19.71 Bn 0.39
2 Johnson & Johnson 613.84 Bn 532.37 Bn 17.26 Bn 0.24
3 AbbVie 502.13 Bn 475.24 Bn 12.70 Bn 0.52
4 Merck 367.76 Bn 322.14 Bn 12.21 Bn 0.42
5 Novartis Ag 298.08 Bn 262.07 Bn 11.24 Bn 0.08
6 Astrazeneca 262.03 Bn 235.71 Bn 12.86 Bn 0.28
7 Amgen 235.81 Bn 191.21 Bn 7.24 Bn 0.60
8 Gilead Sciences 190.97 Bn 165.17 Bn 6.22 Bn 0.53
9 Pfizer 169.66 Bn 116.31 Bn 10.94 Bn 0.31
10 Immunome 2.06 Bn 28.21 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 0.01
Dec 31, 2020 0.01
Sep 30, 2020 0.04
API Access

Immunome Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=IMNM&period=max&api_key=YOUR_API_KEY